Metsera, Inc.
MTSR
Rankning i aktier
#2575
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Aktiekurs
$70.50
Senast synkroniserad: 2025-11-14
Marknadsvärde
$7.33B
Förändring (1 dag)
0.00%
Förändring (1 år)
33.60%
Land
US
Handel Metsera, Inc. (MTSR)
Kategori
Healthcare
Historik för aktiesplit för Metsera, Inc. (MTSR)
Aktien Metsera, Inc. (symbol: MTSR) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Oct 22, 2026.
En MTSR-aktie köpt före Oct 22, 2026 motsvarar nu 0 MTSR-aktier.
Den senaste spliten skedde den Oct 22, 2026.
En MTSR-aktie köpt före Oct 22, 2026 motsvarar nu 0 MTSR-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | |||
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|